Search This Blog

Monday, March 1, 2021

How specialized centers try to treat Covid long-haulers

 As the coronavirus pandemic in the U.S. appears to be turning a corner, another health crisis is brewing: Covid-19 survivors struggling to bounce back to their former selves.

Of the more than 28 million Americans diagnosed with Covid-19, an estimated 10 to 30 percent — possibly as many as 8.4 million people — fall into the category commonly known as "long-haulers."


Despite the staggering numbers, there's no clear diagnosis, no standard care and no national guidelines for how these patients should be treated. There are hopeful signs, however. At special clinics around the country, a better understanding of the condition is emerging, according to a new analysis by NBC News.


NBC News identified more than 80 "post-Covid" clinics nationwide that are actively engaging with Covid-19 patients who continue to have symptoms months after their acute infection cleared. The 64 clinics surveyed by NBC News have seen nearly 10,000 patients — most likely just a sliver of the true number of people affected by a condition only recently given a name by the National Institutes of Health: "Post-Acute Sequelae of SARS-CoV-2 infection," or PASC. Millions of others may be seeking care with a personal physician or suffering alone.

Patients at the 64 clinics are men and women of all ages. Some had to be hospitalized with Covid-19, while many others never became that sick during their acute infection.

The majority are coping with a wide range of lingering symptoms, including life-altering fatigue, ongoing shortness of breath, headaches, even hair loss.

NIH researchers hope to provide answers now that Congress has approved $1.15 billion to study long-term symptoms of Covid-19.

"28 million people in the United States have had Covid," said the NIH's director, Dr. Francis Collins. "If even 1 percent of them have chronic, long-term consequences, that's a whole lot of people. We need to find out everything we can about how to help them."

Help will take time. While the NIH combs through electronic health records, large data banks and collects specimens from patients, for people coping with persistent symptoms now, it's up to hospital systems and doctors to find relief for them.

'Staring at the walls'

Rory Martinson, 57, of Lakeville, Minnesota, is one of those patients. Diagnosed with Covid-19 in November, Martinson has been a patient at the Covid Activity Rehabilitation Program at the Mayo Clinic in Rochester, Minnesota, since early December.

Martinson was on a hunting trip, in a tree, 12 feet off the ground, when he started feeling sick. Staying in a family cabin with a teenage nephew in Park Rapids, Minnesota, Martinson spent nights sweating through fevers and the days trying to stay alert.

"I was worried I was going to fall out of the tree stand," Martinson said.

Martinson's temperature soared to 103 degrees. Upon his return home, his family insisted that he see a doctor. Martinson spent the next 16 days in the hospital, barely able to breathe on his own.

Nearly four months later, Martinson has no detectable virus in his system. But he still gets winded easily. To increase his blood oxygen levels, his rehabilitation at the Mayo Clinic has included breathing exercises, light cardio and weightlifting.

He's also learning how to do household chores, like vacuuming, in ways that use less energy. Instead of standing in one spot and moving the vacuum with his arms and his upper body, Martinson now operates the vacuum in a way that resembles mowing the lawn.

"You burn a lot more energy using your upper body than you do your lower body," Martinson said. His endurance is building back up, albeit very slowly.

"If I wouldn't have found this program," Martinson said, "I know I would still be sitting at home staring at the walls thinking, 'Why am I not getting better?'"

'No magic medication'

NBC News found that there is no medical standard of treatment for post-Covid-19 patients. Therapies vary from traditional physical therapy to medications to mindfulness. Some patients have improved; many others haven't.

"It's very hard," said Dr. Cyrilyn Walters, medical director of ambulatory services at Regional One Health in Memphis, Tennessee, "because there's not a lot of data." Her team, which partnered with the University of Tennessee Health Science Center, works with each patient to rule out conditions unrelated to Covid-19 that could be causing a patient's symptoms. Otherwise, she said, "there is no magic medication."

Dr. Rebecca Keith, an associate professor of pulmonary and critical care medicine at National Jewish Health in Denver, is a co-director of the facility's post-Covid-19 clinic. The facility puts together a "unique care plan" for every patient, she said. Some may need help with breathing. Others have problems with racing hearts. Many complain of constant stomach illness.

"It takes a multidisciplinary approach to try to help people," she said. "Hopefully, as time goes on, science will catch up and we'll have more to offer."

Dr. Carla Sevin, director of the ICU Recovery Center at Vanderbilt University Medical Center in Nashville, Tennessee, said: "If you still need oxygen, you probably need a pulmonologist. If you have heart issues, you probably need a cardiologist. But for some of these other symptoms, it's not really clear who the best person is to see you.

"Because Covid is basically a new disease, we know nothing about the natural history or the recovery or the long-term implications," Sevin said.

Often, the only real options for clinicians are to work with patients on the basics of a healthy lifestyle, including sleep, diet and exercise.

Adding to the difficulty, many clinic appointments are telehealth only because of the pandemic.

To help with brain fog, a commonly reported symptom, the Post Covid Recovery Team at Family Health West in Fruita, Colorado, uses speech therapists to help patients find the right words while speaking.

For people with ongoing headaches, Dr. Ellen Price at Family Health West uses Botox injections, massage and acupuncture.

At the post-Covid-19 clinic at University Hospital of Brooklyn SUNY Downstate in New York City patients with ongoing shortness of breath are given typical medications, such as inhaled or oral allergy drugs.

Surprisingly, some get relief from eating oranges.

While there is no research suggesting the citrus fruit helps treat long-lasting Covid-19 symptoms, Dr. Mafuzur Rahman suggests a benefit from vitamin C or that the juice helps clear congestion.

"Since there are no contra-indications to eating oranges for most patients, I recommend it," Rahman, vice chair of medicine at SUNY Downstate, wrote in an email.

Most long-haul patients seeking treatment at UT Southwestern Medical Center in Dallas benefit from physical therapy to help with breathing, as well as emotional support and counseling, a spokesperson said.

A picture slowly coming into focus

Research into long-haulers has been painfully slow, patients say.

Part of that is simply because for much of the past year, hospitals have been singularly focused on treating the severely ill Covid-19 patients filling up their intensive care units.

"We understand that the medical community is completely and totally overwhelmed," said Amy Watson, 48, of Portland, Oregon. "But we've been awfully patient out here for a year now."

It was Watson, a preschool teacher, who came up with the name "long-haulers." She remembers sitting in her living room weeks after her Covid-19 diagnosis, unable to shake symptoms, including fever and extreme exhaustion.

That was nearly one year ago.

As an increasing number of patients seek help, a clearer picture of typical long-haulers is emerging. Many are otherwise healthy adults in the prime of their lives with careers and families.

Patients report brain fog, an inability to multitask, trouble breathing, gastrointestinal problems, such as diarrhea, as well as profound fatigue.

"Patients are reporting that they need about a four- to five-hour nap after doing something as simple as taking their laundry up a flight of steps or taking out the trash," said Dr. Greg Vanichkachorn, an occupational medicine specialist at the Mayo Clinic. "It can be quite severe and debilitating."


From once being able to play with their kids or run around, "now they can barely get up, take a shower and pick something to eat without feeling incredibly fatigued," said Walters, of Regional One Health in Memphis.

Long-haulers appear to have a problem with the autonomic nervous system, which controls things the body does automatically, without thinking, such as blood vessel constriction, said Vanichkachorn, who's involved with Martinson's treatment. That may help explain why some patients have trouble with irregular heart rhythms or experience sudden changes in blood pressure.

How do you treat a disease you can't define?

Despite some similarities among long-haulers — often women in their 30s, 40s and 50s — there is no consensus on how to diagnose patients. Not all patients have specific lung imaging that would suggest post-Covid-19 illness, for example.

"The lungs aren't even all wrecked in the same way," said Vanderbilt's Sevin. "There are a bunch of different patterns."

Clinics also vary in determining who is eligible for treatment. Asking for a positive test result may not be possible: Many long-haulers became infected before widespread testing was available. Some clinics require patients to have had symptoms for a certain time period, from a few weeks to a few months.

Dr. Sarah Jolley, a pulmonary and critical care specialist at UCHealth University of Colorado Hospital in Aurora, called for the medical community to create standardized definitions and guidelines of care.

Learning from other long-term illnesses

Often, clinicians are relying on their experience treating other long-term illnesses.

It's long been known that patients hospitalized for extended periods in intensive care units can develop cognitive impairment and muscle weakness — usually because of strong sedatives. Recovery and rehabilitation can take six months or longer.

Those who specialize in post-intensive care syndrome are pivoting to help those with long-lasting Covid-19.

Plans for a post-ICU clinic at the UCHealth hospital in Aurora were already in place when the pandemic began, Jolley said. Covid-19 "really accelerated the creation of the clinic, because we anticipated that there would be a large number of ICU patients who needed ongoing care."

The clinic evolved to include post-Covid-19 patients "across the spectrum of illness," Jolley said, including long-haulers.

Clinicians are also taking cues from what's known about other, similar long-lasting illnesses, such as chronic fatigue syndrome and fibromyalgia.

"Many of these patients throughout the history of medicine had been marginalized, just because it was a very fuzzy type of diagnosis," said Vanichkachorn of the Mayo Clinic.

The rapid rise in the number of long-haul patients may spur research for those conditions, as well.

"Research teams are being built to understand what's going on at the chemical level" of those conditions, Vanichkachorn said.

A sense of abandonment

Patients often arrive at the clinics after being turned away by other providers who either dismissed their illness as "all in their head" or could offer no help. The emotional fallout leads to guilt and self-doubt.

"The one universal thing that I've seen across all patients with post-Covid syndrome is, unfortunately, a sense of abandonment," Vanichkachorn said. "Patients often wonder: 'Why am I different from everyone else? Does this syndrome say something about my character or about my constitution or toughness?'"

Patients who were physically fit before Covid-19 infection — special operations military personnel, airline pilots and runners — tend to have more severe long-term symptoms, another mystery of the disease. Up to 30 percent of long-haulers are so debilitated that they have been forced to quit work, according to the Mayo clinic's estimates.

Watson, a marathon runner, is among the patients who never returned to work. She can barely walk a mile without getting winded.

"I want so badly to have the quality of life that I had before," Watson said. "No one wants this to be real life."

https://www.nbcnews.com/health/health-news/inside-post-covid-clinics-how-specialized-centers-are-trying-treat-n1258879

Sharp Drop Seen in COVID Testing As New Cases Plateau

 The amount of COVID-19 testing being done in the United States has fallen by 30 percent in recent weeks, even though testing can curb the spread of coronavirus and spot new outbreaks quickly.

From a high of nearly 14 million tests a week in early January, the pace fell to fewer than 10 million — a level not seen since October — for the week ended Feb. 24, The New York Times reported.

But Dr. Anthony Fauci, the nation's top infectious diseases expert, warned Sunday that Americans shouldn't get complacent because the number of new cases is now leveling off.

"Let's get many, many more people vaccinated," Fauci said on the CBS show, Face the Nation. "And then you could pull back on those types of public health measures. But right now, as we're going down and [then] plateauing, is not the time to declare victory because we're not victorious yet."

As of Monday, 75.2 million Americans have been vaccinated, with nearly 24.8 million people getting their second shot, according to the U.S. Centers for Disease Control and Prevention.

As for drops on COVID-19 testing, some areas are reporting even sharper declines: Michigan is testing about half as many people now as it was in November, and Delaware's state-run sites are testing about one-third as many. Los Angeles County's sites, which were running flat out last month, tested just 35 percent of their capacity last week, the Times reported.

Experts suggested that several factors could be fueling the testing slump, the Times reported:

  • Fewer exposures: Since new coronavirus infections have fallen sharply, fewer people may be having contacts that would prompt them to seek a test.
  • Less travel: The holiday rush is over, reducing the need for testing before or after trips.
  • Bad weather: The severe storms and Arctic temperatures that battered much of the country caused many testing sites to close temporarily.
  • The vaccine rollout: Some states have shifted their limited resources, and their public messaging, toward vaccination efforts at the expense of testing.
  • Pandemic fatigue: Some experts worry the decline may be yet another symptom of public exhaustion with pandemic precautions and safety measures.


All those forces could be at play, Dr. Jennifer Nuzzo, of the Johns Hopkins Bloomberg School of Public Health, told the Times.

"My sense is that it's probably that there are fewer options for testing, fewer communications about it, people may be perceiving that it's less necessary — maybe they just don't see the point any more," she said. But, "there's nothing about the current situation that has made testing any less necessary."

Less testing makes it harder to follow the virus's mutations and to get ahead of variants that may be more contagious or deadly, Dr. Rick Pescatore, the chief physician at the Delaware Division of Public Health, told the Times. "We can't identify variants until we first identify positives," he said.

https://www.usnews.com/news/health-news/articles/2021-03-01/sharp-drop-seen-in-covid-testing-as-new-cases-plateau

Biden administration taking new NY Covid variant ‘very seriously’: Fauci

 The Biden administration is taking the emergence of a new coronavirus strain in New York “very seriously,” White House Chief Medical Advisor Dr. Anthony Fauci said Monday.

The new strain, which researchers are calling B.1.526, is rapidly spreading in New York City and carries a mutation that could weaken the effectiveness of vaccines, according to The New York Times. The variant first appeared in November and now accounts for about 1-in-4 viral sequences, the Times reports.

Fauci said Monday the strain likely originated in Washington Heights, a neighborhood in the uppermost area of Manhattan, before spreading to other boroughs. He said U.S. officials need to “keep an eye” on the strain, including the possibility that it could evade the protection of antibody treatments and vaccines.

“We are certainly taking the New York variant, the 526, very seriously,” Fauci said during a White House news briefing.

U.S. health officials are growing worried that the emergence of new, highly contagious variants could reverse the downward trajectory in infections in the United States and delay the nation’s recovery from the pandemic. They are also pushing Americans to get vaccinated as quickly as possible before potentially new and even more dangerous variants continue to take hold.

At the same news briefing, the head of the Centers for Disease Control and Prevention, Dr. Rochelle Walensky, said she is “really worried” about some states rolling back public health measures intended to contain the pandemic as U.S. cases appear to be leveling off at a “very high number” of 70,000 cases per day.

“Seventy thousand cases a day seems good compared to where we were just a few months ago,” she said. “Please hear me clearly: At this level of cases with variants spreading, we stand to completely lose the hard-earned ground we have gained.”

In addition to the B.1.526 strain in New York, officials are monitoring four other variants. As of Sunday, the CDC has identified 2,400 cases of the B.1.1.7 variant, first identified in the U.K. The agency has identified 53 cases of the B.1.351 strain from South Africa as well as 10 cases of P.1, a variant first identified in Brazil. California scientists are also monitoring a variant called B.1.427/B.1.429.

Fauci said Monday that there are a lot of “unknowns” about the New York variant, but officials are looking at the strain “very carefully.”

https://www.cnbc.com/2021/03/01/new-york-variant-fauci-says-biden-administration-is-taking-covid-strain-very-seriously.html

Nearly 400K doses of J&J COVID-19 vaccine headed to CA

 Nearly 4 million doses of Johnson & Johnson's single-dose COVID-19 vaccine are headed to states, including California, with injections expected to start as early as Tuesday.


The White House says the entire stockpile of the newly approved vaccine went out Sunday night. J&J will deliver about 16 million more doses by the end of March and 100 million total by the end of June, but the distribution would be backloaded.
According to Gov. Gavin Newsom, California is expected to receive about 380,000 doses this week.

Unlike the Moderna and Pfizer vaccines, Johnson & Johnson's shot requires only one dose and doesn't need a specialized freezer for storage, making it easier to administer.

The newest vaccine has shown to be 85% effective in preventing severe or critical illness.

At clinical trials, it has also shown to be effective against the South African and Brazilian variants.

Doctors say just because its efficacy is slightly lower than that of Moderna and Pfizer's vaccines, this is a not a second-rate vaccine.

Johnson & Johnson's CEO appeared on Good Morning America on Monday.

"We're shipping 4 million (doses) over the next several days, we then expect to have about 20 million having been delivered by March and then we'll be on this path to do 100 million by June of this year," Alex Gorsky said. "And remember that's all en route to doing almost a billion doses over the course of 2021."


Inovio developing vaccines to target coronavirus variants

 U.S. drug developer Inovio Pharmaceuticals Inc said on Monday it was developing next-generation COVID-19 vaccine candidates that could be tailored to the known and potentially the unknown SARS-CoV-2 variants.

Inovio began developing a COVID-19 vaccine last year, but is running behind rivals who have already introduced vaccines in the United States. A late-stage U.S. study of Inovio’s vaccine candidate is expected to start in the second quarter of 2021.

https://www.reuters.com/article/us-health-coronavirus-inovio-pharma/inovio-developing-vaccines-to-target-coronavirus-variants-idUSKCN2AT3ND

Novavax COVID-19 shot could be cleared for U.S. use as early as May: CEO

 Novavax Inc’s chief executive said on Monday its COVID-19 vaccine could be cleared for use in the United States as soon as May if U.S. regulators authorize it based on data from the company’s British trial, which could be completed as soon as April.

Novavax can already manufacture its shots at scale and will be able to have tens of millions of doses stockpiled and ready to ship in the United States when it receives authorization, Chief Executive Stanley Erck said.

“It will be substantial - in the many tens of millions or a hundred million,” Erck said in an interview.

Novavax had promised to deliver 110 million doses to the U.S. government by the end of the third quarter. That could happen as early as July, Erck said.

The timeline for U.S. authorization would get pushed back to June or July if regulators choose to wait for Novavax to complete its U.S.-based trial before reviewing the vaccine, he said.

Novavax on Monday reported that its net loss widened to $177.6 million, or $2.70 per share, in the fourth quarter, from $31.8 million, or $1.13 per share a year earlier.

Boosted by vaccine business, revenue rose to $279.7 million from $8.8 million a year earlier.

Novavax promised to deliver doses to the United States after it was awarded $1.6 billion to help finance research, development and production of a COVID-19 vaccine.

An early data readout in January from its UK trial showed the vaccine to be around 96% effective against the original version of the coronavirus and around 86% effective against the now widely circulating variant first discovered in Britain.

Novavax completed enrollment of its 30,000-subject U.S.-based trial in February.

https://www.reuters.com/article/us-novavax-results/novavax-covid-19-shot-could-be-cleared-for-u-s-use-by-may-ceo-idUSKCN2AT3MD

Emergent Bio a Buy on Vaccine News: Cramer

 Emergent and Johnson & Johnson have a manufacturing agreement for JNJ's  (JNJ) - Get Report COVID-19 vaccine. 

The vaccine, which received an emergency use authorization from the Food & Drug Administration over the weekend, is now the third vaccine to start being distributed in the United States.

Per a press release from July 2020, "Under the agreement, Emergent will begin providing large-scale drug substance manufacturing for Johnson & Johnson’s adenovirus-based COVID-19 vaccine in 2021, upon successful completion of the activities under the previously executed Technology Transfer Agreement. For the subsequent years beginning 2023, Emergent will provide a flexible capacity deployment model to support additional drug substance batches annually."

https://www.thestreet.com/video/jim-cramer-emergent-bio-buy-jnj-vaccine